<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="30271">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02123017</url>
  </required_header>
  <id_info>
    <org_study_id>CPI-KR-005</org_study_id>
    <nct_id>NCT02123017</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Bisacodyl and Lactulose as a Preparation for Colonoscopy</brief_title>
  <official_title>An Observer-blinded, Dose-finding Study to Investigate the Safety, Efficacy, and Patient Preference of Lactulose for Oral Solution With Bisacodyl for Cleansing of the Colon as a Preparation for Colonoscopy in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cumberland Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cumberland Pharmaceuticals</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy and safety of bisacodyl combined with
      escalating doses of lactulose to be used as a  preparation for colonoscopy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Efficacy of bisacodyl and lactulose as a preparation for colonoscopy.</measure>
    <time_frame>10-14 hours post last consumption</time_frame>
    <safety_issue>No</safety_issue>
    <description>Efficacy assessed by the physician's determination of the cleanliness of the colon using the Boston Bowel Preparation Scale (BBPS).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of bisacodyl and lactulose as a bowel evacuant</measure>
    <time_frame>1 day post last consumption</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Safety determined by the incidence and severity of treatment emergent adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability of and preference for bisacodyl and lactulose as a bowel evacuant</measure>
    <time_frame>1 day post last consumption</time_frame>
    <safety_issue>No</safety_issue>
    <description>Tolerability assessed by a patient questionnaire.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Colonoscopy Preparation</condition>
  <arm_group>
    <arm_group_label>Increasing Levels of Lactulose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 cohorts of 12 patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bisacodyl and Lactulose</intervention_name>
    <description>3 cohorts of up to 12 patients, each receiving 15 mg of bisacodyl and 108 ounces of water.  Additionally, the first cohort will  take 90 grams of lactulose and subsequent cohorts will consume 135 or 180 grams according to the dose escalating protocol.</description>
    <arm_group_label>Increasing Levels of Lactulose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients requiring bowel evacuation for colonoscopy.

        Exclusion Criteria:

          -  Patients with galactosemia (galactose-sensitive diet).

          -  Patients known to be hypersensitive to any of the components of lactulose for oral
             solution.

          -  Patients with a known abnormality on screening or a vital sign assessments that, in
             the Investigator's judgment, may pose a significant risk including those pertaining
             to dehydration or electrolyte shifts.

          -  Patients with a history of impaired renal function.

          -  Patients with current or recent history of hypotension, as defined by the
             Investigator.

          -  Patients with a history of long Q-T syndrome.

          -  Patients with a history of a failed bowel preparation.

          -  Patients with severe constipation, defined as those patients taking daily
             prescription or over-the-counter laxatives.

          -  Patients with possible bowel obstruction, gastric retention, bowel perforation, toxic
             colitis, toxic megacolon, ileus or previous colonic surgery (except hemorrhoidectomy
             and polypectomy).

          -  Patients on lactulose therapy or receiving any treatment for chronic constipation.

          -  Be pregnant or nursing.

          -  Patients expected to require electrocautery or argon plasma coagulation.

          -  Patients less than 18 years of age.

          -  Inability to understand the requirements of the study or be unwilling to provide
             written informed consent (as evidenced by signature on an informed consent document
             approved by an Institutional Review Board [IRB]) and agree to abide by the study
             restrictions.

          -  Be otherwise unsuitable for the study, in the opinion of the Investigator.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Krause, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ClinSearch, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amy Rock, PhD</last_name>
    <phone>615.255.0068</phone>
    <email>arock@cumberlandpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>ClinSearch, LLC</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37421</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Richard Krause, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 23, 2014</lastchanged_date>
  <firstreceived_date>April 23, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bowel Evacuation</keyword>
  <keyword>Colonoscopy Preparation</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bisacodyl</mesh_term>
    <mesh_term>Lactulose</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
